Get Real Time Here
| Open2.140 | Close- |
| Vol / Avg.45.762K / 53.580K | Mkt Cap35.543M |
| Day Range2.140 - 2.260 | 52 Wk Range2.000 - 6.190 |
Gain Therapeutics Stock (NASDAQ:GANX), Quotes and News Summary
Gain Therapeutics Stock (NASDAQ: GANX) stock price, news, charts, stock research, profile.
| Open2.140 | Close- |
| Vol / Avg.45.762K / 53.580K | Mkt Cap35.543M |
| Day Range2.140 - 2.260 | 52 Wk Range2.000 - 6.190 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.450 | -0.370 | 0.0800 | ||||
| REV | 0 |
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.310 | -0.620 | -0.3100 | ||||
| REV | 1.010M | 0 | -1.010M |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-09-18 | HC Wainwright & Co. | Raghuram Selvaraju | Reiterates | BuyBuy | Maintains | - | 10.00 |
| 2023-09-12 | Maxim Group | Jason McCarthy | Initiates Coverage On | Buy | Announces | - | 10.00 |
| 2023-08-31 | HC Wainwright & Co. | Raghuram Selvaraju | Reiterates | BuyBuy | Maintains | - | 10.00 |
| 2023-08-14 | Chardan Capital | Keay Nakae | Reiterates | BuyBuy | Maintains | - | 6.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| GANX | Gain Therapeutics | 4.67% | 35.5M |
| OCX | OncoCyte | -3.68% | 30.2M |
| INTS | Intensity Therapeutics | 30.59% | 43.9M |
| COEP | Coeptis Therapeutics | -2.56% | 38.9M |
| BOLT | Bolt Biotherapeutics | 12.54% | 36.4M |
How do I buy Gain Therapeutics (GANX) stock?
You can purchase shares of Gain Therapeutics (NASDAQ: GANX) through any online brokerage.
Who are Gain Therapeutics's (GANX) competitors?
Other companies in Gain Therapeutics’s space includes: OncoCyte (NASDAQ:OCX), Intensity Therapeutics (NASDAQ:INTS), Coeptis Therapeutics (NASDAQ:COEP), Bolt Biotherapeutics (NASDAQ:BOLT) and Precision BioSciences (NASDAQ:DTIL).
What is the target price for Gain Therapeutics (GANX) stock?
The latest price target for Gain Therapeutics (NASDAQ: GANX) was reported by HC Wainwright & Co. on Monday, September 18, 2023. The analyst firm set a price target for 10.00 expecting GANX to rise to within 12 months (a possible 346.43% upside). 11 analyst firms have reported ratings in the last year.
Current Stock Price for Gain Therapeutics (GANX)?
The stock price for Gain Therapeutics (NASDAQ: GANX) is $2.24 last updated Today at December 1, 2023 at 8:08 PM UTC.
Does Gain Therapeutics (GANX) pay a dividend?
There is no dividend information for Gain Therapeutics.
When is Gain Therapeutics (NASDAQ:GANX) reporting earnings?
Gain Therapeutics’s Q3 earnings are confirmed for Tuesday, November 14, 2023.
Is Gain Therapeutics (GANX) going to split?
There is no upcoming split for Gain Therapeutics.
What sector and industry does Gain Therapeutics (GANX) operate in?
Gain Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.